Am J Psychiatry 156:1686-1696, November 1999
© 1999 American Psychiatric Association
Antipsychotic-Induced Weight Gain: A Comprehensive Research Synthesis
David B. Allison, Ph.D.,
Janet L. Mentore, M.S.Ed.,
Moonseong Heo, Ph.D.,
Linda P. Chandler, Ph.D.,
Joseph C. Cappelleri, Ph.D., M.P.H.,
Ming C. Infante, M.S., and
Peter J. Weiden, M.D.
OBJECTIVE: The purpose of this study was to estimate and compare the effects of antipsychotics—both the newer ones and the conventional ones—on body weight. METHOD: A comprehensive literature search identified 81 English- and non-English-language articles that included data on weight change in antipsychotic-treated patients. For each agent, a meta-analysis and random effects metaregression estimated the weight change after 10 weeks of treatment at a standard dose. A comprehensive narrative review was also conducted on all articles that did not yield quantitative information but did yield important qualitative information. RESULTS: Placebo was associated with a mean weight reduction of 0.74 kg. Among conventional agents, mean weight change ranged from a reduction of 0.39 kg with molindone to an increase of 3.19 kg with thioridazine. Among newer antipsychotic agents, mean increases were as follows: clozapine, 4.45 kg; olanzapine, 4.15 kg; sertindole, 2.92 kg; risperidone, 2.10 kg; and ziprasidone, 0.04 kg. Insufficient data were available to evaluate quetiapine at 10 weeks. CONCLUSIONS: Both conventional and newer antipsychotics are associated with weight gain. Among the newer agents, clozapine appears to have the greatest potential to induce weight gain, and ziprasidone the least. The differences among newer agents may affect compliance with medication and health risk.
This article has been cited by other articles:
|
|
|
|
 
S. Eker, A. Sarandol, C. Akkaya, E. Sivrioglu, and S. Kirli
The potential relationship between QTc interval prolongation and ziprasidone treatment: three cases
J Psychopharmacol,
November 1, 2009;
23(8):
993 - 996.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. U. Correll, P. Manu, V. Olshanskiy, B. Napolitano, J. M. Kane, and A. K. Malhotra
Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents
JAMA,
October 28, 2009;
302(16):
1765 - 1773.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. L. Breden, M. T. Liu, and S. R. Dean
Metabolic and Cardiac Side Effects of Second-generation Antipsychotics: What Every Clinician Should Know
Journal of Pharmacy Practice,
October 1, 2009;
22(5):
478 - 488.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. Lichwala-Zyla, J. H. Price, J. A. Dake, T. Jordan, and J. A. Price
Psychiatrists' Perceptions and Practices in Treating Patients' Obesity
Acad Psychiatry,
September 1, 2009;
33(5):
370 - 376.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Carmel and J. M. Gorman
Classifying Antipsychotics by Likelihood of Metabolic Side-Effects
Psychiatr Serv,
August 1, 2009;
60(8):
1143 - 1143.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. M. Laursen, T. Munk-Olsen, E. Agerbo, C. Gasse, and P. B. Mortensen
Somatic Hospital Contacts, Invasive Cardiac Procedures, and Mortality From Heart Disease in Patients With Severe Mental Disorder
Arch Gen Psychiatry,
July 1, 2009;
66(7):
713 - 720.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Andersohn, R. Schade, S. Suissa, and E. Garbe
Long-Term Use of Antidepressants for Depressive Disorders and the Risk of Diabetes Mellitus
Am J Psychiatry,
May 1, 2009;
166(5):
591 - 598.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. E. Dean and P. D. Thuras
Mortality and tardive dyskinesia: long-term study using the US National Death Index
The British Journal of Psychiatry,
April 1, 2009;
194(4):
360 - 364.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. E. Morden, L. A. Mistler, W. B. Weeks, and S. J. Bartels
Health Care for Patients with Serious Mental Illness: Family Medicine's Role
J Am Board Fam Med,
March 1, 2009;
22(2):
187 - 195.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. W. Haupt, L. C. Rosenblatt, E. Kim, R. A. Baker, R. Whitehead, and J. W. Newcomer
Prevalence and Predictors of Lipid and Glucose Monitoring in Commercially Insured Patients Treated With Second-Generation Antipsychotic Agents
Am J Psychiatry,
March 1, 2009;
166(3):
345 - 353.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. M. Linck, A. P. Herrmann, A. L. Piato, B. C. Detanico, M. Figueiro, J. Florio, M. M. Iwu, C. O. Okunji, M. B. Leal, and E. Elisabetsky
Alstonine as an Antipsychotic: Effects on Brain Amines and Metabolic Changes
Evid. Based Complement. Altern. Med.,
February 2, 2009;
(2009)
nep002v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Storfjell, E. Brigell, K. Christiansen, J. McDevitt, A. Miller, M. Snyder, and D. Pavick
WOW Specialty Home Care Service for Individuals With Serious Mental Illness
Home Health Care Management Practice,
December 1, 2008;
21(1):
23 - 32.
[Abstract]
[PDF]
|
|
|
|
|
|
|
O. Sentissi, J. Epelbaum, J.-P. Olie, and M.-F. Poirier
Leptin and Ghrelin Levels in Patients With Schizophrenia During Different Antipsychotics Treatment: A Review
Schizophr Bull,
November 1, 2008;
34(6):
1189 - 1199.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. D Volkow, G.-J. Wang, J. S Fowler, and F. Telang
Overlapping neuronal circuits in addiction and obesity: evidence of systems pathology
Phil Trans R Soc B,
October 12, 2008;
363(1507):
3191 - 3200.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Paciullo
Evaluating the association between clozapine and venous thromboembolism
Am. J. Health Syst. Pharm.,
October 1, 2008;
65(19):
1825 - 1829.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Gentile
Antipsychotic Therapy During Early and Late Pregnancy. A Systematic Review
Schizophr Bull,
September 11, 2008;
(2008)
sbn107v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. L. Jensen
Drug-Induced Hyperphagia: What Can We Learn From Psychiatric Medications?
JPEN J Parenter Enteral Nutr,
September 1, 2008;
32(5):
578 - 581.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Snigdha, C. Thumbi, G. Reynolds, and J. Neill
Ziprasidone and aripiprazole attenuate olanzapine-induced hyperphagia in rats
J Psychopharmacol,
July 1, 2008;
22(5):
567 - 571.
[Abstract]
[PDF]
|
|
|
|
|
|
|
O. O. Yevtushenko, S. J. Cooper, R. O'Neill, J. K. Doherty, J. V. Woodside, and G. P. Reynolds
Influence of 5-HT2C receptor and leptin gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophrenia
The British Journal of Psychiatry,
June 1, 2008;
192(6):
424 - 428.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Sernyak and R. A. Rosenheck
Antipsychotic Use in the Treatment of Outpatients With Schizophrenia in the VA From Fiscal Years 1999 to 2006
Psychiatr Serv,
May 1, 2008;
59(5):
567 - 569.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Morgan, M. Sargeant, J. Chukwuma, and G. Hughes
Audit of metabolic syndrome in adults prescribed clozapine in community and long-stay in-patient populations
Psychiatr. Bull.,
May 1, 2008;
32(5):
174 - 177.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. S. Fenton and M. R. Chavez
Medication-Induced Weight Gain and Dyslipidemia in Patients With Schizophrenia
Focus,
April 1, 2008;
6(2):
246 - 253.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. G. Ondo, D. Jong, and A. Davis
Comparison of Weight Gain in Treatments for Tourette Syndrome: Tetrabenazine Versus Neuroleptic Drugs
J Child Neurol,
April 1, 2008;
23(4):
435 - 437.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R.-R. Wu, J.-P. Zhao, X.-F. Guo, Y.-Q. He, M.-S. Fang, W.-B. Guo, J.-D. Chen, and L.-H. Li
Metformin Addition Attenuates Olanzapine-Induced Weight Gain in Drug-Naive First-Episode Schizophrenia Patients: A Double-Blind, Placebo-Controlled Study
Am J Psychiatry,
March 1, 2008;
165(3):
352 - 358.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Fell, J. Neill, N. Anjum, L. Peltola, and K. Marshall
Investigation into the influence of a high fat diet on antipsychotic-induced weight gain in female rats
J Psychopharmacol,
March 1, 2008;
22(2):
182 - 186.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R.-R. Wu, J.-P. Zhao, H. Jin, P. Shao, M.-S. Fang, X.-F. Guo, Y.-Q. He, Y.-J. Liu, J.-D. Chen, and L.-H. Li
Lifestyle Intervention and Metformin for Treatment of Antipsychotic-Induced Weight Gain: A Randomized Controlled Trial
JAMA,
January 9, 2008;
299(2):
185 - 193.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Weber, M. Colon, and M. Nelson
Pilot Study of a Cognitive Behavioral Group Intervention to Prevent Further Weight Gain in Hispanic Individuals With Schizophrenia
Journal of the American Psychiatric Nurses Association,
January 1, 2008;
13(6):
353 - 359.
[Abstract]
[PDF]
|
|
|
|
|
|
|
T. R. E. Barnes, C. Paton, M.-R. Cavanagh, E. Hancock, D. M. Taylor, and on behalf of the UK Prescribing Observatory for Me
A UK Audit of Screening for the Metabolic Side Effects of Antipsychotics in Community Patients
Schizophr Bull,
November 1, 2007;
33(6):
1397 - 1403.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. S. Jarboe
Considering the Impact on Overall Patient Health When Choosing Antipsychotic Therapy
Journal of the American Psychiatric Nurses Association,
November 1, 2007;
13(5_suppl):
S23 - S28.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. M. McClellan
Olanzapine and Pediatric Bipolar Disorder: Evidence for Efficacy and Safety Concerns
Am J Psychiatry,
October 1, 2007;
164(10):
1462 - 1464.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L Dufresne
Weighing In: Emergent Diabetes Mellitus and Second-Generation Antipsychotics
Ann. Pharmacother.,
October 1, 2007;
41(10):
1725 - 1727.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Malone, R. M. Carnahan, and E. C. Kutscher
Antipsychotic Medication Use in the Elderly Patient
Journal of Pharmacy Practice,
August 1, 2007;
20(4):
318 - 326.
[Abstract]
[PDF]
|
|
|
|
|
|
|
W.S. Leslie, C.R. Hankey, and M.E.J. Lean
Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review
QJM,
July 1, 2007;
100(7):
395 - 404.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A.H. Barnett, P. Mackin, I. Chaudhry, A. Farooqi, R. Gadsby, A. Heald, J. Hill, H. Millar, R. Peveler, A. Rees, et al.
Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia
J Psychopharmacol,
June 1, 2007;
21(4):
357 - 373.
[Abstract]
[PDF]
|
|
|
|
|
|
|
G.D. Cooper, L.C. Pickavance, J.P.H. Wilding, J.A. HarroLd, J.C.G. HaLford, and A.J. Goudie
Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities
J Psychopharmacol,
June 1, 2007;
21(4):
405 - 413.
[Abstract]
[PDF]
|
|
|
|
|
|
|
References
PsychiatryOnline CME,
May 1, 2007;
2007(1):
2 - 2.
[Full Text]
|
|
|
|
|
|
|
J. M. Noel
ASHP Therapeutic Position Statement on the Use of Second-Generation Antipsychotic Medications in the Treatment of Adults with Psychotic Disorders
Am. J. Health Syst. Pharm.,
April 15, 2007;
64(8):
863 - 876.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. C.W. Lau, J. D. Douketis, K. M. Morrison, I. M. Hramiak, A. M. Sharma, E. Ur, and for members of the Obesity Canada Clinical Practic
2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]
Can. Med. Assoc. J.,
April 10, 2007;
176(8):
S1 - S13.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. C.W. Lau, J. D. Douketis, K. M. Morrison, I. M. Hramiak, A. M. Sharma, E. Ur, and pour les membres du Groupe d'experts d'Obesite Can
Lignes directrices canadiennes de 2006 sur la prise en charge et la prevention de l'obesite chez les adultes et les enfants [sommaire]
Can. Med. Assoc. J.,
April 10, 2007;
176(8):
SF1 - SF14.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. W. Goldberg, J. A. Kreyenbuhl, D. R. Medoff, F. B. Dickerson, K. Wohlheiter, L. J. Fang, C. H. Brown, and L. B. Dixon
Quality of Diabetes Care Among Adults With Serious Mental Illness
Psychiatr Serv,
April 1, 2007;
58(4):
536 - 543.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.-K. Wu, C.-K. Wang, Y.-M. Bai, C.-Y. Huang, and S.-D. Lee
Outcomes of Obese, Clozapine-Treated Inpatients With Schizophrenia Placed on a Six-Month Diet and Physical Activity Program
Psychiatr Serv,
April 1, 2007;
58(4):
544 - 550.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. F. Kim, A. S. Huang, A. M. Snowman, C. Teuscher, and S. H. Snyder
From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase
PNAS,
February 27, 2007;
104(9):
3456 - 3459.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Y. Meltzer
Illuminating the molecular basis for some antipsychotic drug-induced metabolic burden
PNAS,
February 27, 2007;
104(9):
3019 - 3020.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Archie, J. O. Goldberg, N. Akhtar-Danesh, J. Landeen, L. McColl, and J. McNiven
Psychotic Disorders, Eating Habits, and Physical Activity: Who Is Ready for Lifestyle Changes?
Psychiatr Serv,
February 1, 2007;
58(2):
233 - 239.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Roberts, A. Roalfe, S. Wilson, and H. Lester
Physical health care of patients with schizophrenia in primary care: a comparative study
Fam. Pract.,
February 1, 2007;
24(1):
34 - 40.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Straker, P. A. Shapiro, and P. R. Muskin
Aripiprazole in the Treatment of Delirium
Psychosomatics,
October 1, 2006;
47(5):
385 - 391.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. S. Fenton and M. R. Chavez
Medication-Induced Weight Gain and Dyslipidemia in Patients With Schizophrenia
Am J Psychiatry,
October 1, 2006;
163(10):
1697 - 1704.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. L. Lambert, F. E. Cunningham, D. R. Miller, G. W. Dalack, and K. Hur
Diabetes Risk Associated with Use of Olanzapine, Quetiapine, and Risperidone in Veterans Health Administration Patients with Schizophrenia
Am. J. Epidemiol.,
October 1, 2006;
164(7):
672 - 681.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Lamberti, D. Olson, J. F. Crilly, T. Olivares, G. C. Williams, X. Tu, W. Tang, K. Wiener, S. Dvorin, and M. B. Dietz
Prevalence of the Metabolic Syndrome Among Patients Receiving Clozapine
Am J Psychiatry,
July 1, 2006;
163(7):
1273 - 1276.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. L. Olson, T. Delate, and D. J. Duagn
Monitoring of Patients Given Second-Generation Antipsychotic Agents
Psychiatr Serv,
July 1, 2006;
57(7):
1045 - 1046.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. L. Kirk, M. Cahir, and G. P. Reynolds
Clozapine, but not haloperidol, increases neuropeptide Y neuronal expression in the rat hypothalamus
J Psychopharmacol,
July 1, 2006;
20(4):
577 - 579.
[Abstract]
[PDF]
|
|
|
|
|
|
|
G. P. Reynolds, M. J. Hill, and S. L. Kirk
The 5-HT2C receptor and antipsychoticinduced weight gain - mechanisms and genetics
J Psychopharmacol,
July 1, 2006;
20(4_suppl):
15 - 18.
[Abstract]
[PDF]
|
|
|
|
|
|
|
W. K. Kroeze and B. L. Roth
Screening the receptorome
J Psychopharmacol,
July 1, 2006;
20(4_suppl):
41 - 46.
[Abstract]
[PDF]
|
|
|
|
|
|
|
Z. T. Bloomgarden
Atypical Antipsychotic Agents, Retinopathy, Nephropathy, and Cardiovascular Disease.
Diabetes Care,
June 1, 2006;
29(6):
1439 - 1446.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. I Brixner, Q. Said, P. K Corey-Lisle, A V. Tuomari, G. J L'Italien, W. Stockdale, and G. M Oderda
Naturalistic Impact of Second-Generation Antipsychotics on Weight Gain
Ann. Pharmacother.,
April 1, 2006;
40(4):
626 - 632.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Gianfrancesco, J. Pesa, R.-H. Wang, and H. Nasrallah
Assessment of antipsychotic-related risk of diabetes mellitus in a Medicaid psychosis population: Sensitivity to study design
Am. J. Health Syst. Pharm.,
March 1, 2006;
63(5):
431 - 441.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. A Marken and R. W Pies
Emerging Treatments for Bipolar Disorder: Safety and Adverse Effect Profiles
Ann. Pharmacother.,
February 1, 2006;
40(2):
276 - 285.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Hosojima, T. Togo, T. Odawara, K. Hasegawa, S. Miura, Y. Kato, A. Kanai, A. Kase, H. Uchikado, and Y. Hirayasu
Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia
J Psychopharmacol,
January 1, 2006;
20(1):
75 - 79.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. J. Weiden
Switching antipsychotics: an updated review with a focus on quetiapine
J Psychopharmacol,
January 1, 2006;
20(1):
104 - 118.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K. Rasmussen, M. J. Benvenga, F. P. Bymaster, D. O. Calligaro, I. R. Cohen, J. F. Falcone, S. K. Hemrick-Luecke, F. M. Martin, N. A. Moore, L. K. Nisenbaum, et al.
Preclinical Pharmacology of FMPD [6-Fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: A Potential Novel Antipsychotic with Lower Histamine H1 Receptor Affinity Than Olanzapine
J. Pharmacol. Exp. Ther.,
December 1, 2005;
315(3):
1265 - 1277.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. B. Zipursky, H. Gu, A. I. Green, D. O. Perkins, M. F. Tohen, J. P. McEvoy, S. M. Strakowski, T. Sharma, R. S. Kahn, R. E. Gur, et al.
Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol
The British Journal of Psychiatry,
December 1, 2005;
187(6):
537 - 543.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Malone
Medications Associated with Weight Gain
Ann. Pharmacother.,
December 1, 2005;
39(12):
2046 - 2054.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Best, A. P. Yates, and G. P. Reynolds
Actions of antipsychotic drugs on pancreatic {beta}-cell function: contrasting effects of clozapine and haloperidol
J Psychopharmacol,
November 1, 2005;
19(6):
597 - 601.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. Haddad
Weight change with atypical antipsychotics in the treatment of schizophrenia
J Psychopharmacol,
November 1, 2005;
19(6_suppl):
16 - 27.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. Tighe and T. Dinan
An overview of the central control of weight regulation and the effect of antipsychotic medication
J Psychopharmacol,
November 1, 2005;
19(6_suppl):
36 - 46.
[Abstract]
[PDF]
|
|
|
|
|
|
|
H. Ascher-Svanum, M. D. Stensland, B. J. Kinon, and G. D. Tollefson
Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic
J Psychopharmacol,
November 1, 2005;
19(6_suppl):
110 - 117.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. McDevitt, J. Wilbur, J. Kogan, and J. Briller
A Walking Program for Outpatients in Psychiatric Rehabilitation: Pilot Study
Biol Res Nurs,
October 1, 2005;
7(2):
87 - 97.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. A. Lieberman, T. S. Stroup, J. P. McEvoy, M. S. Swartz, R. A. Rosenheck, D. O. Perkins, R. S.E. Keefe, S. M. Davis, C. E. Davis, B. D. Lebowitz, et al.
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
N. Engl. J. Med.,
September 22, 2005;
353(12):
1209 - 1223.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. A. Graham, H. Gu, J. A. Lieberman, J. B. Harp, and D. O. Perkins
Double-Blind, Placebo-Controlled Investigation of Amantadine for Weight Loss in Subjects Who Gained Weight With Olanzapine
Am J Psychiatry,
September 1, 2005;
162(9):
1744 - 1746.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. WEST and S. J. BRASINGTON
Complications From Olanzapine in a Mentally Healthy Patient
Am J Psychiatry,
September 1, 2005;
162(9):
1756 - 1756.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. REMINGTON
Rational pharmacotherapy in early psychosis
The British Journal of Psychiatry,
August 1, 2005;
187(48):
s77 - s84.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. L. Leslie and R. A. Rosenheck
Pharmacotherapy and Health Care Costs Among Patients With Schizophrenia and Newly Diagnosed Diabetes
Psychiatr Serv,
July 1, 2005;
56(7):
803 - 809.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Malone, S. A Alger-Mayer, and D. A Anderson
Medication Associated with Weight Gain May Influence Outcome in a Weight Management Program
Ann. Pharmacother.,
July 1, 2005;
39(7):
1204 - 1208.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. M. Gardner, R. J. Baldessarini, and P. Waraich
Modern antipsychotic drugs: a critical overview
Can. Med. Assoc. J.,
June 21, 2005;
172(13):
1703 - 1711.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Straker, C. U. Correll, E. Kramer-Ginsberg, N. Abdulhamid, F. Koshy, E. Rubens, R. Saint-Vil, J. M. Kane, and P. Manu
Cost-Effective Screening for the Metabolic Syndrome in Patients Treated With Second-Generation Antipsychotic Medications
Am J Psychiatry,
June 1, 2005;
162(6):
1217 - 1221.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Miceli, K. D. Wilner, S. K. Swan MD, and T. G. Tensfeldt
Pharmacokinetics, Safety, and Tolerability of Intramuscular Ziprasidone in Healthy Volunteers
J. Clin. Pharmacol.,
June 1, 2005;
45(6):
620 - 630.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Schooler, J. Rabinowitz, M. Davidson, R. Emsley, P. D. Harvey, L. Kopala, P. D. McGorry, I. Van Hove, M. Eerdekens, W. Swyzen, et al.
Risperidone and Haloperidol in First-Episode Psychosis: A Long-Term Randomized Trial
Am J Psychiatry,
May 1, 2005;
162(5):
947 - 953.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. C. Henderson, P. M. Copeland, T. B. Daley, C. P. Borba, C. Cather, D. D. Nguyen, P. M. Louie, A. E. Evins, O. Freudenreich, D. Hayden, et al.
A Double-Blind, Placebo-Controlled Trial of Sibutramine for Olanzapine-Associated Weight Gain
Am J Psychiatry,
May 1, 2005;
162(5):
954 - 962.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Dunlop, A. L. Sabb, H. Mazandarani, J. Zhang, S. Kalgaonker, E. Shukhina, S. Sukoff, R. L. Vogel, G. Stack, L. Schechter, et al.
WAY-163909 [(7bR, 10aR)-1,2,3,4,8,9,10,10a-Octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole], a Novel 5-Hydroxytryptamine 2C Receptor-Selective Agonist with Anorectic Activity
J. Pharmacol. Exp. Ther.,
May 1, 2005;
313(2):
862 - 869.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. A. Nasrallah, S. D. Targum, R. Tandon, J. S. McCombs, and R. Ross
Defining and Measuring Clinical Effectiveness in the Treatment of Schizophrenia
Psychiatr Serv,
March 1, 2005;
56(3):
273 - 282.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. R. Richardson, G. Faulkner, J. McDevitt, G. S. Skrinar, D. S. Hutchinson, and J. D. Piette
Integrating Physical Activity Into Mental Health Services for Persons With Serious Mental Illness
Psychiatr Serv,
March 1, 2005;
56(3):
324 - 331.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Ader, S. P. Kim, K. J. Catalano, V. Ionut, K. Hucking, J. M. Richey, M. Kabir, and R. N. Bergman
Metabolic Dysregulation With Atypical Antipsychotics Occurs in the Absence of Underlying Disease A Placebo-Controlled Study of Olanzapine and Risperidone in Dogs
Diabetes,
March 1, 2005;
54(3):
862 - 871.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E K. Hester and M. R Thrower
Current Options in the Management of Olanzapine-Associated Weight Gain
Ann. Pharmacother.,
February 1, 2005;
39(2):
302 - 310.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. A. Graham, D. O. Perkins, L. J. Edwards, R. C. Barrier Jr., J. A. Lieberman, and J. B. Harp
Effect of Olanzapine on Body Composition and Energy Expenditure in Adults With First-Episode Psychosis
Am J Psychiatry,
January 1, 2005;
162(1):
118 - 123.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. W. Buchanan, M. P. Ball, E. Weiner, B. Kirkpatrick, J. M. Gold, R. P. McMahon, and W. T. Carpenter Jr.
Olanzapine Treatment of Residual Positive and Negative Symptoms
Am J Psychiatry,
January 1, 2005;
162(1):
124 - 129.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. HOLZER, G. PAIVA, and O. HALFON
Quetiapine-Induced Weight Gain and Escitalopram
Am J Psychiatry,
January 1, 2005;
162(1):
192 - 193.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. C. Henderson, E. Cagliero, P. M. Copeland, C. P. Borba, E. Evins, D. Hayden, M. T. Weber, E. J. Anderson, D. B. Allison, T. B. Daley, et al.
Glucose Metabolism in Patients With Schizophrenia Treated With Atypical Antipsychotic Agents: A Frequently Sampled Intravenous Glucose Tolerance Test and Minimal Model Analysis
Arch Gen Psychiatry,
January 1, 2005;
62(1):
19 - 28.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. B. Schur, L. Sikich, R. L. Findling, R. P. Malone, M. L. Crismon, A. Derivan, J. C. MacIntyre II, E. Pappadopulos, L. Greenhill, N. Schooler, et al.
Treatment Recommendations for the Use of Antipsychotics for Aggressive Youth (TRAAY), Part I: A Review
Focus,
October 1, 2004;
2(4):
596 - 607.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. M. Simpson, I. D. Glick, P. J. Weiden, S. J. Romano, and C. O. Siu
Randomized, Controlled, Double-Blind Multicenter Comparison of the Efficacy and Tolerability of Ziprasidone and Olanzapine in Acutely Ill Inpatients With Schizophrenia or Schizoaffective Disorder
Am J Psychiatry,
October 1, 2004;
161(10):
1837 - 1847.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. dosReis, P. L. Owens, K. B. Puccia, and P. J. Leaf
Multimodal Treatment for ADHD Among Youths in Three Medicaid Subgroups: Disabled, Foster Care, and Low Income
Psychiatr Serv,
September 1, 2004;
55(9):
1041 - 1048.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. L. Leslie and R. A. Rosenheck
Incidence of Newly Diagnosed Diabetes Attributable to Atypical Antipsychotic Medications
Am J Psychiatry,
September 1, 2004;
161(9):
1709 - 1711.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. P. Reynolds
Receptor Mechanisms in the treatment of Schizophrenia
J Psychopharmacol,
September 1, 2004;
18(3):
340 - 345.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. V. Seeman
Gender Differences in the Prescribing of Antipsychotic Drugs
Am J Psychiatry,
August 1, 2004;
161(8):
1324 - 1333.
[Abstract]
[Full Text]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 1999
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
